{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:45:39Z","timestamp":1792075539716,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020975","name":"UCB Pharma France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis (MG) is a chronic autoimmune disease with symptoms of muscle weakness and fatigability. The aim of this study was to estimate MG-related healthcare resource use (HCRU), associated direct costs and their determinants in France. Data were extracted from the French national claims database (SNDS) for the period 1\/1\/2008\u201331\/12\/2019. Adult patients with MG were identified using an algorithm based primarily on the G70 ICD-10 code. The incident and prevalent MG populations were compared with matched non-MG controls and direct costs were estimated. An exploratory indirect cost analysis restricted to sick leave and disability was also performed and a multivariable model used to identify patients\u2019 characteristics associated with higher direct MG costs. In 2019, the mean annual direct cost per patient with MG was \u20ac8,506 compared with \u20ac3,670 in controls, leading to an MG-excess cost of \u20ac4,836 per patient. Patients with MG had significantly (p\u2009&lt;\u20090.0001) higher HCRU than controls in all items of inpatient and outpatient care. MG-excess costs were high, especially in the first year after disease identification and were mainly driven by hospitalizationsfor crises and exacerbations. They remained relatively stable thereafter. Patients with MG were on sick leave more often and for longer periods and were 2\u20133 times more likely to receive disability or living allowance than controls. The highest costs were concentrated during the first year after MG identification due to exacerbations and crises requiring hospitalization with costly medications and procedures. Novel innovative treatments are expected to change these main drivers of medical costs.<\/jats:p>","DOI":"10.1007\/s10198-026-01975-8","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:28:55Z","timestamp":1792063735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic burden of myasthenia gravis in France: A nationwide claims database study (STAMINA)"],"prefix":"10.1007","author":[{"given":"G\u00e9rard","family":"De Pouvourville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Laforet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Salort-Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-7275","authenticated-orcid":false,"given":"Anne","family":"Crochard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Chollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Nevoret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bou\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Tard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"49","key":"1975_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin, S., M. Frenkian-Cuvelier, and B. Eymard. 2014. Diagnostic and clinical classification of autoimmune myasthenia gravis. Journal of Autoimmunity 48 (49): 143\u2013148. https:\/\/doi.org\/10.1016\/j.jaut.2014.01.003.","journal-title":"Journal of Autoimmunity"},{"issue":"7","key":"1975_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","volume":"22","author":"S Blum","year":"2015","unstructured":"Blum, S., D. Lee, D. Gillis, D. F. Mceniery, S. Reddel, and P. Mccombe. 2015. Clinical features and impact of myasthenia gravis disease in Australian patients. Journal of Clinical Neuroscience 22 (7): 1164\u20131169.","journal-title":"Journal of Clinical Neuroscience"},{"issue":"1","key":"1975_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-024-12768-5","volume":"272","author":"C Bugge","year":"2024","unstructured":"Bugge, C., I. Engebretsen, I. S. Kristiansen, E. M. S\u00e6ther, I. Lindberg-Schager, F. Arneberg, and N. E. Gilhus. 2024. Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) - A register-based study. Journal of Neurology 272 (1): 15.","journal-title":"Journal of Neurology"},{"issue":"12","key":"1975_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088813","volume":"14","author":"JP Camdessanch\u00e9","year":"2024","unstructured":"Camdessanch\u00e9, J. P., S. Sacconi, A. Archer, P. Boulanger, A. Crochard, J. P. Bertocchio, A. Richard, P. E. Villy, and G. Sol\u00e9. 2024. SPOON: An observational, cross-sectional study of perceptions and expectations of adults with generalised myasthenia gravis in France. British Medical Journal Open 14 (12) : e088813. https:\/\/doi.org\/10.1136\/bmjopen-2024-088813.","journal-title":"British Medical Journal Open"},{"issue":"10","key":"1975_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46.PMID:20565885;PMCID:PMC2905354","volume":"18","author":"AS Carr","year":"2010","unstructured":"Carr, A. S., C. R. Cardwell, P. O. McCarron, and J. McConville. 2010. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurology 18 (10): 46. https:\/\/doi.org\/10.1186\/1471-2377-10-46.PMID:20565885;PMCID:PMC2905354.","journal-title":"BMC Neurology"},{"key":"1975_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-140045","volume":"2","author":"JCW Deenen","year":"2015","unstructured":"Deenen, J. C. W., C. G. C. Horlings, J. J. G. M. Verschuuren, and A. L. M. Verbeek. 2015. 2021 The epidemiology of neuromuscular disorders: A comprehensive overview of the literature. J Neuromuscul Dis 2:73\u201385.","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"1975_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16233","volume":"31","author":"I Engebretsen","year":"2024","unstructured":"Engebretsen, I., N. E. Gilhus, I. S. Kristiansen, E. M. S\u00e6ther, I. Lindberg-Schager, F. Arneberg, and C. Bugge. 2024. The epidemiology and societal costs of myasthenia gravis in Norway: A non-interventional study using national registry data. European Journal of Neurology 31 (5) : e16233. https:\/\/doi.org\/10.1111\/ene.16233.","journal-title":"European Journal of Neurology"},{"key":"1975_CR8","doi-asserted-by":"publisher","unstructured":"Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. 2018 Feb 27. https:\/\/doi.org\/10.1002\/mus.26114. Epub ahead of print. PMID: 29486521.","DOI":"10.1002\/mus.26114"},{"issue":"1","key":"1975_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12883-016-0757-2","volume":"16","author":"A Frost","year":"2016","unstructured":"Frost, A., M. L. Svendsen, J. Rahbek, C. M. Stapelfeldt, C. V. Nielsen, and T. Lund. 2016. Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997\u20132011: a Danish nationwide cohort study. BMC Neurol 16 (1): 224.","journal-title":"BMC Neurol"},{"issue":"10","key":"1975_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus, N. E., and J. J. Verschuuren. 2015. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurology 14 (10): 1023\u20131036.","journal-title":"Lancet Neurology"},{"issue":"6","key":"1975_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill, J. T., A. Marano, A. Krueger, and D. B. Sanders. 2011. Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve 44 (6): 907\u201311. https:\/\/doi.org\/10.1002\/mus.22212.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1975_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","volume":"22","author":"L Harris","year":"2022","unstructured":"Harris, L., S. Graham, S. MacLachlan, A. Exuzides, and S. Jacob. 2022. A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurology 22 (1): 172.","journal-title":"BMC Neurology"},{"issue":"2","key":"1975_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","volume":"13","author":"C Heatwole","year":"2011","unstructured":"Heatwole, C., N. Johnson, R. Holloway, and K. Noyes. 2011. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: An acute hospital cost comparison study. Journal of Clinical Neuromuscular Disease 13 (2): 85\u201394. https:\/\/doi.org\/10.1097\/CND.0b013e31822c34dd.","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"7","key":"1975_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt, E., O. Pogoryelova, T. Sejersen, N. Zethraeus, A. Breiner, and H. Lochm\u00fcller. 2020. Economic costs of myasthenia gravis: A systematic review. PharmacoEconomics 38 (7): 715\u2013728.","journal-title":"PharmacoEconomics"},{"issue":"2","key":"1975_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/MRR.0b013e32831e4587","volume":"32","author":"M Leonardi","year":"2009","unstructured":"Leonardi, M., A. Raggi, C. Antozzi, P. Confalonieri, L. Maggi, F. Cornelio, et al. 2009. Disability and functional profiles of patients with myasthenia gravis measured with ICF classification. International Journal of Rehabilitation Research 32 (2): 167\u2013172.","journal-title":"International Journal of Rehabilitation Research"},{"key":"1975_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221150327","volume":"16","author":"M Mahic","year":"2023","unstructured":"Mahic, M., A. Bozorg, J. Rudnik, P. Zaremba, and A. Scowcroft. 2023. Healthcare resource use in myasthenia gravis: A US health claims analysis. Therapeutic Advances in Neurological Disorders 16 : 17562864221150327.","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"6","key":"1975_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat, A., H. J. Kaminski, G. Cutter, B. Katirji, and A. Alshekhlee. 2010. Comparative analysis of therapeutic options used for myasthenia gravis. Annals of Neurology 68 (6): 797\u2013805. https:\/\/doi.org\/10.1002\/ana.22139.","journal-title":"Annals of Neurology"},{"key":"1975_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza, R., and C. Antozzi. 2018. When myasthenia gravis is deemed refractory: Clinical signposts and treatment strategies. Therapeutic Advances in Neurological Disorders 11 : 1756285617749134.","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"1975_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami, P., D. B. Sanders, G. Wolfe, et al. 2021. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96:114\u2013122.","journal-title":"Neurology"},{"key":"1975_CR20","first-page":"157","volume":"29","author":"A Parthan","year":"2023","unstructured":"Parthan, A., M. Royston, A. Thanataveerat, E. L. East, C. S. Parzynski, and A. A. Habib. 2023. Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States. Muscle & Nerve 29:157\u2013165.","journal-title":"Muscle & Nerve"},{"key":"1975_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16511","volume":"31","author":"F Piehl","year":"2024","unstructured":"Piehl, F., J. Vissing, J. Meht\u00e4l\u00e4, et al. 2024. Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population-based registry study. European Journal of Neurology 31 : e16511.","journal-title":"European Journal of Neurology"},{"key":"1975_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120480","volume":"443","author":"CZ Qi","year":"2022","unstructured":"Qi, C. Z., T. Hughes, D. Gelinas, Y. Li, A. Goyal, E. Brauer, A. Bhuwalka, M. Sato, S. Jadhav, and G. Phillips. 2022. Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States. Journal of the Neurological Sciences 443 : 120480. https:\/\/doi.org\/10.1016\/j.jns.2022.120480.","journal-title":"Journal of the Neurological Sciences"},{"key":"1975_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0, F., E. Salort-Campana, S. Jacob, E. Cort\u00e9s-Vicente, and C. Schneider-Gold. 2024. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. European Journal of Neurology 31 : e16180. https:\/\/doi.org\/10.1111\/ene.16180.","journal-title":"European Journal of Neurology"},{"key":"1975_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari, N., B. Fatahi, Y. Bartina, et al. 2021. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: A systematic review and meta-analysis. Journal of Translational Medicine 19 : 516.","journal-title":"Journal of Translational Medicine"},{"issue":"3","key":"1975_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neurol.2023.09.004","volume":"180","author":"E Salort-Campana","year":"2024","unstructured":"Salort-Campana, E., P. Laforet, G. de Pouvourville, A. Crochard, G. Chollet, C. Nevoret, C. Emery, S. Bou\u00e9e, and C. Tard. 2024. Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA). Revue Neurologique (Paris) 180 (3): 202\u2013210.","journal-title":"Revue Neurologique (Paris)"},{"issue":"4","key":"1975_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders, D. B., G. I. Wolfe, M. Benatar, A. Evoli, N. E. Gilhus, I. Illa, N. Kuntz, J. M. Massey, A. Melms, H. Murai, M. Nicolle, J. Palace, D. P. Richman, J. Verschuuren, and P. Narayanaswami. 2016. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 87 (4): 419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790.","journal-title":"Neurology"},{"key":"1975_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold, C., T. Hagenacker, N. Melzer, and T. Ruck. 2019. Understanding the burden of refractory myasthenia gravis. Therapeutic Advances in Neurological Disorders 12 : 1756286419832242.","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"1975_CR28","doi-asserted-by":"crossref","unstructured":"Sharma A, Roy B, Khokhar B, Nowak R, \u00ab Burden of Disease in Patients with Refractory Myasthenia Gravis (P5.4\u2013037) \u00bb, Neurology, vol. 92, no 15 Supplement, apr. 2019, Supplement\/P5.4\u2013037","DOI":"10.1212\/WNL.92.15_supplement.P5.4-037"},{"key":"1975_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint17100163","volume":"17","author":"S Takahashi","year":"2025","unstructured":"Takahashi, S., and R. Kinno. 2025. Management of myasthenic crisis and emerging roles of molecularly targeted therapies: A narrative review. Neurology International 17 : 163.","journal-title":"Neurology International"},{"key":"1975_CR30","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1007\/s00415-024-12714-5","volume":"271","author":"C Tard","year":"2024","unstructured":"Tard, C., P. Laforet, G. de Pouvourville, et al. 2024. Treatment of myasthenia gravis in France: A retrospective claims database study (STAMINA). Journal of Neurology 271:7239\u20137249. https:\/\/doi.org\/10.1007\/s00415-024-12714-5.","journal-title":"Journal of Neurology"},{"key":"1975_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120531","volume":"445","author":"A Ting","year":"2023","unstructured":"Ting, A., T. Story, C. Lecomte, A. Estrin, S. Syed, and E. Lee. 2023. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment. Journal of the Neurological Sciences 445 : 120531.","journal-title":"Journal of the Neurological Sciences"},{"issue":"Suppl 4","key":"1975_CR32","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin, P., J. Rudant, P. Constantinou, et al. 2017. Value of a national administrative database to guide public decisions: From the Syst\u00e8me National d\u2019Information Interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS) in France. Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique 65 (Suppl 4): S149-s167.","journal-title":"Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"},{"issue":"6","key":"1975_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","volume":"94","author":"A Uzawa","year":"2023","unstructured":"Uzawa, A., S. Suzuki, S. Kuwabara, H. Akamine, Y. Onishi, M. Yasuda, Y. Ozawa, N. Kawaguchi, T. Kubota, M. P. Takahashi, Y. Suzuki, G. Watanabe, T. Kimura, T. Sugimoto, M. Samukawa, N. Minami, M. Masuda, S. Konno, Y. Nagane, and K. Utsugisawa. 2023. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. Journal of Neurology, Neurosurgery, and Psychiatry 94 (6): 467\u2013473. https:\/\/doi.org\/10.1136\/jnnp-2022-330519.","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"2","key":"1975_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJGM Verschuuren","year":"2022","unstructured":"Verschuuren, J. J. G. M., J. Palace, H. Murai, M. R. Tannemaat, H. J. Kaminski, and V. Bril. 2022. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology 21 (2): 189\u2013202.","journal-title":"Lancet Neurology"},{"issue":"2","key":"1975_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000529583","volume":"57","author":"H Wartmann","year":"2023","unstructured":"Wartmann, H., S. Hoffmann, T. Ruck, C. Nelke, B. Deiters, and T. Volmer. 2023. Incidence, prevalence, hospitalization rates, and treatment patterns in myasthenia gravis: A 10-year real-world data analysis of German claims data. Neuroepidemiology 57 (2): 121\u2013128.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"1975_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918.PMID:23983833;PMCID:PMC3726100","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell, L. C., and J. M. Levine. 2011. Myasthenic crisis. Neurohospitalist. 1 (1): 16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918.PMID:23983833;PMCID:PMC3726100.","journal-title":"Neurohospitalist."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-01975-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01975-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:03:11Z","timestamp":1792072991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-01975-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":36,"alternative-id":["1975"],"URL":"https:\/\/doi.org\/10.1007\/s10198-026-01975-8","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}